An interventional study of Response Inhibition and Deep Brain Stimulation in Parkinson's disease in Movement Disorders, sponsored by University of Alabama at Birmingham. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-17.
Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 203 studies in Movement Disorders with a site in United States — 52 open to participants now, 59 under way, 2 of them phase 3. Movement Disorders · United States.
Among the 203 studies in Movement Disorders with a site in United States, this one is the 43rd largest by planned enrollment of the 117 interventional ones that give a count, is one of 10 that started in 2019, is one of 50 with no phase, reaches primary completion later than 32 of the 55 other live ones, and was the 110th registered.
373 studies on the registry are indexed under Movement Disorders; 104 are open to participants now.
Browse Movement Disorders studies →52 of the 203 studies in Movement Disorders with a site in United States are open now. Recruiting first, the newest first:
Vima Therapeutics · Sites in United States, Canada
Ages 18–65
Yale University · Sites in United States
Ages 40–80
University Hospitals Cleveland Medical Center · Sites in United States
Ages 18–89
Peter C. Gerszten, MD · Sites in United States
Ages 21–75 · Healthy volunteers
University of California, Los Angeles · Sites in United States
Ages 18–90
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 75 Movement Disorders studies recruiting now, 30 (40%) set no upper age limit and 18 (24%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
203 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 39 · Phase 3 12 · Phase 4 3
First in 1989; this study’s year is marked. 10 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 47 across 222 interventional studies indexed under Movement Disorders.
Median enrollment 50 across the 117 interventional studies, 60 across the 84 observational. Of the 129 that completed or were terminated, 31 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
63 of 203 have an industry lead sponsor. The 10 most frequent:
University of Alabama at Birmingham is the lead sponsor of 1,422 studies on the registry; 277 are open to participants now.
Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.
University of Alabama at Birmingham has 3 studies filed under Movement Disorders — fewer than ten, so there is no comparison to draw.
17 of the studies in Movement Disorders with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07599592University of California, Los AngelesOpen Label Study for the Use of Low Intensity Focused Ultrasound for Essential Tremor | 2026-12-31 |
| NCT07428447CND Life SciencesAnalysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease | 2027-02 |
| NCT06602193Denali Therapeutics Inc.Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD) | 2027-03 |
| NCT02553525Duke UniversityEffects of Stimulation Patterns of Deep Brain Stimulation | 2027-03 |
| NCT05822388Medical University of South CarolinaCognitive Decline Following Deep Brain Stimulation | 2027-03-31 |
Add all 17 to your calendar (.ics) → With an account.
Among the 203 studies in Movement Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the brain activity associated with motor and non-motor symptoms of movement disorders, including Parkinson's disease (PD) and essential tremor. These movement disorders commonly have significant non-motor features, such as depression, cognitive and memory impairment, decreased attention, speech and language disturbances, and slower processing speeds. The investigators are interested in the brain activity associated with these motor and non-motor symptoms, and propose to investigate changes in brain activity while the investigators perform recordings of the surface and deep structures of the brain, in addition to the typical recordings the investigators perform, during routine deep brain stimulation (DBS) surgery.
Movement disorders are a prominent cause of disability worldwide. In the United States, it is estimated that more than 4 million people suffer from Parkinson's disease (PD), essential tremor (ET), and dystonia, making them some of the most prevalent of neurologic disorders. Of these, PD is the most common, and is primarily characterized by tremor, rigidity, and bradykinesia. However, though primarily characterized by motor symptoms, many patients also have prominent non-motor features, including depression and cognitive impairment, with deficiencies in processing speed, memory, attention, and learning. Some of the most debilitating cognitive deficiencies include deficits in goal-directed response selection and response inhibition, language, and/or speech difficulties, all of which substantially contribute to reduced quality of life.
Unfortunately, these features of movement disorders are less well-studied and lack effective treatment options, necessitating that new treatments be investigated. Deep brain stimulation (DBS), while a highly effective treatment for the cardinal features of PD, is essentially ineffective for, and can even worsen other cognitive domains, and there are few studies currently investigating how different parameters of DBS may improve these symptoms. In addition, speech abnormalities are common with Parkinson's disease and DBS can sometimes worsen speech problems. These impairments consists primarily of hypophonia, but cognitive deficits can result in actual language disturbance. It is often difficult to know whether the speech problems are related to language processing or articulation (related to the movement disorder). In an effort to begin addressing these questions, we propose to study motor and non-motor symptoms in patients with movement disorders, and to correlate movement and cognition with underlying neural electrophysiology.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Parkinson's Disease Patients receiving DBS electrodes
Procedure: Response Inhibition and Deep Brain Stimulation in Parkinson's disease
Control subjects will be non-Parkinson's Disease patients with essential tremor
After creation of the burr hole and prior to DBS electrode placement, 1-2 subdural strip electrodes will be placed anteriorly or posteriorly from the cranial opening. These electrodes are routinely placed using this technique for seizure mapping, with arrays of electrodes (up to 6) being placed around the perimeter of the opening.14 Subdural strips vary in length and contact size (e.g., the 6-contact Ad-Tech strip), and are currently placed predominantly for studies of sensorimotor function,13 including at our institution (IRB-140327003). Placement over prefrontal areas is performed at other institutions.11-13 The DBS surgery will then proceed according to routine practice, and following lead placement in the optimal desired location, the research task paradigm will begin.
Accuracy via Simon Task (% correct)
In the Simon task, participants are instructed to respond with a right or left button press (Right = Red, Left = Blue) according to how a word is printed on a screen ("RED" or "BLUE"), regardless of the color in which the word is printed. This is a measurement of accuracy (% correct, ranging from 0-100, with higher scores indicating better performance)
Time frame: Baseline
Response times via Simon Task (sec)
In the Simon task, participants are instructed to respond with a right or left button press according to the word "RIGHT" or "LEFT" that appears on a screen, regardless of where on the screen it actually appears. This is a measurement response times (continuous measure, from 0-4000 milliseconds) between correct and incorrect responses.
Time frame: Baseline
Simon Effect on Response times (sec)
Participants will perform the Simon task as described, and the Simon effect will be calculated as the difference in response times between congruent and incongruent trials
Time frame: Baseline
Simon Effect on Accuracy (% correct)
Participants will perform the Simon task as described, and the Simon effect will be calculated as the difference in accuracy between congruent and incongruent trials
Time frame: Baseline
UPDRS 3 motor score (0-108)
Participants will undergo motor evaluation using the validated United Parkinson's disease Rating Scale (UPDRS) part 3
Time frame: Baseline
Dementia Rating Scale Score (0-144 points)
Participants will undergo neuropsychological testing as part of routine care, including the Dementia Rating Scale
Time frame: Baseline
Started Sep 2019 (actual). Primary completion is estimated for Mar 2028, 102 months after the start.
Of 83 non-industry interventional studies with no phase under Movement Disorders, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 80. This study's planned 102 months is above that.
Counting every sponsor, half of 85 studies reached it within 33 months; a quarter within 11 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Alabama at Birmingham →